AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in AZN shares today? Let’s find out!

AstraZeneca PLC (NYSE:AZN) is lagging the broader market this year so far, with shares declining by over 8%. The ...

A healthcare AI collaboration and a bullish retail outlook lift sentiment, while a Phase 3 trial setback puts EyePoint under ...

Oracle (ORCL) stock rises 1.20% as an AstraZeneca AI collaboration targets faster clinical trial recruitment, healthcare data ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...

AstraZeneca's medicine Wainua did not meet its goal of reducing deaths and recurrent heart-related emergencies in people with a rare heart condition. Shares slumped and were on track for the worst day ...

The AstraZeneca collaboration is a credible wedge into recurring, software-like healthcare AI (Cerner upgrades + trial ...

AstraZeneca stock is trading in the mid-$160 range as a new €2.55 billion eurobond offering and consensus targets above $200 highlight how debt funding and analyst expectations intersect with the ...

Several Oncology Catalysts, One Earnings Question AstraZeneca PLC (NYSE:AZN) enters the3-27 European Society for Medical ...

AstraZeneca (AZN) stock came under pressure on Sept. 29 after the pharma giant announced a massive $2 billion investment in Summit Therapeutics (SMMT). As investors responded to the disclosure, AZN ...